New Hope for Cancertherapy

469 views

Published on

New Hope for Cancertherapy

Published in: Education
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
469
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

New Hope for Cancertherapy

  1. 1. New Hope for Cancertherapy: A New Drug Combination for Chemoimmunotherapy <ul><ul><li></li></ul></ul>
  2. 2. Company Overview <ul><li>Found in 2003, Baofa Cancer Therapeutics Inc. includes: </li></ul><ul><li>A R&D center for development of drug combination regimens and delivery technology </li></ul><ul><li>Two cancer hospitals focusing on intratumoral therapy with the proprietary drug-release technology, which have treated about ten thousand patients </li></ul><ul><li>A medical device company for development, manufacture and marketing of Ozone </li></ul><ul><li>260 employees </li></ul><ul><ul><li></li></ul></ul>
  3. 3. Business Focus <ul><li>Increasing cancer population </li></ul><ul><li>Limited efficacy and significant side effects </li></ul><ul><li>of current treatments, e.g., chemotherapy </li></ul><ul><li>Difficulty in new drug development </li></ul><ul><ul><li></li></ul></ul>New applications of approved drugs Targeted Therapy: physical & molecular targets Combination Therapy: chemoimmunotherapy Personalized Cancer Therapy
  4. 4. <ul><ul><li></li></ul></ul><ul><ul><li></li></ul></ul>TriCancerVac <ul><li>Cytotoxic Drug </li></ul><ul><li>Clinically approved </li></ul><ul><li>Stability </li></ul>Adjuvant Increasing immunogenicity of tumor antigens to boost immune response Oxidant Controlling drug-release
  5. 5. <ul><li>Targeted </li></ul><ul><li> TriCancerVac is injected intratumorally under the guidance </li></ul><ul><li>of an imaging device such as ultrasound or CT scanner. The </li></ul><ul><li>procedure is straightforward as a needle biopsy and more </li></ul><ul><li>easily used than other intervention methods. </li></ul><ul><ul><li></li></ul></ul>Technology Goldberg 2002 Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery . J Pharm Pharmacol. 54:159-80
  6. 6. <ul><li>Sustained Drug Release </li></ul><ul><li>A clinically approved oxidant effectively coagulates tumor mass to </li></ul><ul><li>inhibit blood flow and entrap the injected drugs at high concentration </li></ul><ul><li>within the tumor (>10X conventional chemotherapy) for sustained </li></ul><ul><li>drug release, which improves drug utilization by extending duration </li></ul><ul><li>of drug action and reducing dosing frequency. </li></ul>Technology
  7. 7. <ul><li>Chemoimmunotherapy </li></ul><ul><li>The autologous tumor antigens released from the dead tumor </li></ul><ul><li>cells killed by cytotoxic drug trigger immune response as a self- </li></ul><ul><li>vaccination. Adjuvant boosts systemic immunity against the patient </li></ul><ul><li>specific tumor antigens to suppress and eradicate tumor recurrence </li></ul><ul><li>and metastasis as cancer autologous vaccination. </li></ul>Technology Emens LA. 2008. Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci. 13: 249-57. Lake RA. 2005. Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer. 5(5): 397-405. Nowak AK. 2006. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev. 58:975-90.
  8. 8. Competitive Advantage <ul><li>Simple and Cost-effective </li></ul><ul><li>A 30-45 minute procedure; 1/2 -1/3 of the cost of standard chemotherapy; more applicable than autologous tumor vaccines and catheter interventional chemotherapy. </li></ul><ul><li>Clinically effective for a broad spectrum of tumors </li></ul><ul><li>Patients with various solid tumors including liver, lung and pancreatic cancers are treated with significant increase in survival than the control subjects without adjuvant. </li></ul><ul><li>Minimal side effects and better quality of life </li></ul><ul><li>Since drug is entrapped in the targeted tumor mass with less leakage, it causes only temporary fever (< 38 o C) for a few hours without other systemic cytotoxicity. </li></ul><ul><ul><li></li></ul></ul>Local Chemotherapy Personalized Cancer Therapy Systemic Immunity +
  9. 9. <ul><li>P < 0.05 </li></ul>Clinical Data — Liver Cancer Stage N Median Survival Time (M) Six Month Survival Rate ( % ) One Year Survival Rate ( % ) - Adjuvant Ⅱ 2 2 50 50 Ⅲ 31 4 41.94 29.03 Ⅳ 57 3 24.56 10.53 Sum 90 3.5 32.22 18.89 + Adjuvant Ⅱ 7 30.1 85.71 71.42 Ⅲ 86 7 70.93 31.39 Ⅳ 116 5.5 52.58 25.86 Sum 209 7 61.24 29.67
  10. 10. Clinical Data Pancreatic Cancer Group N Six Month Survival Rate (%) p One Year Survival Rate ( % ) p +Adjuvant 25 64 > 0.05 28 < 0.05 -Adjuvant 20 45 5
  11. 11. Clinical Data — NSCLC* *Patients were treated with intratumoral therapy, followed by supportive treatment (radiotherapy and EP Chemotherapy : CBP 0.3 d 1 , VP-16 0.1 d 1 ~ 4 ) Group Stage N Median Survival Time (M) Six Month Survival Rate (%) One Year Survival Rate (%) - Adjuvant II 10 6.33 50 30 III 20 5.52 45 20 IV 12 4.9 41.67 33.33 Sum 42 7.59 45.23 26.19 + Adjuvant II 8 11.47 100 50 III 33 11.9 69.7 42.42 IV 11 9.77 81.82 45.45 Sum 52 12.66 76.36 45.45
  12. 12. Clinical Data — NSCLC** **Patients were treated with intratumoral therapy alone Group N Mean Survival Time (M) Median Survival Time (M) Six Month Survival Rate ( % ) One Year Survival Rate ( % ) -Adjuvant Ⅰ 2 22.5 4 50 50 Ⅱ 2 4.5 4.5 0 0 Ⅲ 6 3.33 2 16.67 0 Ⅳ 4 6.15 4.5 50 25 Sum 14 7.04 3.5 28.57 14.29 +Adjuvant Ⅰ 5 25.5 13 60 60 Ⅱ 2 14 11 50 50 Ⅲ 11 18.8 10 72.72 45.45 Ⅳ 7 2.86 1 28.57 0 Sum 25 15.29 9 64 36
  13. 13. Clinical Data Relapsed NSCLC Patients were treated with intratumoral therapy, followed by supportive treatment Group N Mean Survival Time (M) Median Survival Time (M) One Year Survival Rate (% ) -Adjuvant 34 7.40 5.32 5.88 +Adjuvant 60 11.99 9.36 20.34
  14. 14. <ul><ul><li></li></ul></ul>Clinical Data — Tumor Response
  15. 15. Clinical Data Side Effect Evaluation SE Sum N % Ⅰ Ⅱ Ⅲ Ⅳ Nausea/Vomit 120 6 6 0 0 10 Hair Loss 120 0 0 0 0 0 Leukopenia 120 2 1 1 0 3.33
  16. 16. Applications <ul><li>Unresectable tumors </li></ul><ul><li>Applied as preoperative treatment to reduce tumor size and to prevent metastasis </li></ul><ul><li>Tumor recurrence or failed to early treatment </li></ul><ul><li>Used with radiotherapy or low-dose chemotherapy to increase efficacy and reduce side effects </li></ul><ul><li>Used as agent for other intervention therapies </li></ul><ul><ul><li></li></ul></ul>
  17. 17. IP Status Australia AU60177024 United States US6811788 China ZL01806830.8
  18. 18. D IND D P C A B ARA-C-T ADM-T E = Exploratory Clinical Testing E Automatic Injector GEMCITABINE-T PTX-T
  19. 19. Partnership <ul><li>Investment/Equity </li></ul><ul><li>Licensing </li></ul><ul><li>Co-development of new regimen </li></ul><ul><li>( e.g., Tarceva-T) </li></ul><ul><ul><li></li></ul></ul>
  20. 20. World Is Smaller Here
  21. 21. <ul><ul><li></li></ul></ul>Thank You www.bfyl.com

×